India Proposes Central Regulatory Oversight for Antimicrobials to Address Resistance
The Indian Health Ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials—including antibiotics, antivirals, and antifungals—under central regulatory oversight. This change would require manufacturers to obtain prior approval from the Central Licensing Authority before state licensing, ensuring stricter scrutiny of quality, safety, efficacy, and bioequivalence. The move aims to address concerns over antimicrobial resistance by preventing substandard products and strengthening regulatory controls, with public feedback invited before finalization.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 55/100.
Outlets measured: businessstandard, economictimes, deccanherald, hindustantimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–65/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
hindustantimes broke this story on 19 Nov, 07:03 am. Other outlets followed.
